125561 -

Another technical reference exists for "Deep fuzzy C-means clustering in a federated heterogeneous scenario," which uses a similar DOI sequence (10.1109/JAS.2025. 125561 ). Public Records & Evidence

A paper titled " Optimal nonparametric inference via deep neural network " is indexed under this number (Article 125561) in the Journal of Mathematical Analysis and Applications .

The identifier appears across several distinct contexts, most notably as an FDA application number for the drug Kanuma and as an article identifier for a research paper on optimal nonparametric inference using deep neural networks. Pharmaceutical: FDA BLA 125561 125561

The application was submitted by Alexion Pharmaceuticals and received FDA approval in September 2015 . Academic & Technical Research

It is an enzyme replacement therapy used to treat Lysosomal Acid Lipase (LAL) deficiency , a rare genetic condition. Another technical reference exists for "Deep fuzzy C-means

The number also serves as a specific article identifier (often part of a DOI or page reference) in various scientific journals:

Under number 125561 , written evidence was submitted by Mrs. C. Roche to the UK Parliament regarding the impact of screen time and "digital drugs" on children’s brains and ADHD . The number also serves as a specific article

It is associated with a study on "Deep reinforcement learning for real-time energy dispatch in smart grids" published in the journal Applied Energy .